The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2023 | Evaluating the use of cell-based therapies in lung cancers
Molly Li, MBBS, Queen Elizabeth Hospital, Hong Kong, discusses our current status on the development of cell-based therapies for lung cancer. Dr Li explains that there is limited clinical data on the use of cellular therapies in lung cancer because of the difficulty in identifying a specific antigen target for tumor-infiltrating lymphocyte (TIL) therapy. Additionally, the immunosuppressive microenvironment present in lung cancer limits the efficacy of cellular therapies in general. Despite these challenges, a Phase I trial (NCT04035486) of a novel TIL therapy with nivolumab in patients with anti-PD-1 resistant lung cancer was shown to be promising. Thus, the lung-cancer-specific hurdles notwithstanding, cellular therapy has a promising outlook in future research. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
